Enrollment has been completed in the first in-human trial for iStar’s microinvasive MINIject glaucoma surgery device, according to a company press release.
The MIGS device will be tested in 25 patients with mild to moderate open-angle glaucoma that is not controlled by topical hypotensives in a prospective, international study. The trial will assess the safety and performance of the device as measured by IOP reduction at 6 months, the release said.
iStar’s MINIject uses “soft and flexible, medical grade silicone which conforms to the eye anatomy,” promoting “biointegration
Uncategorized